Key Segments:
By Test Type
-
Pharmacokinetics
-
Pharmacodynamics
-
Bioavailability and Bioequivalence Studies
-
Other Test Types
By Product Type
-
Cell Therapy
-
Gene Therapy
-
Gene-Modified Cell Therapy
By Stage
-
Clinical
-
Non-Clinical
By Indication
-
Oncology
-
Infectious Diseases
-
Neurological Disorders
-
Rare Genetic Diseases
-
Ophthalmology
-
Cardiovascular and Metabolic Diseases
-
Other Indications
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include BioAgilytix, KCAS Bioanalytical Services, Labcorp Drug Development, IQVIA, Charles River Laboratories, Pharmaron, SGS, Intertek, Eurofins Scientific, and PPD, among others.
Key opportunities include rising non-clinical and early discovery-stage testing demand, expanding gene-modified cell therapy testing needs, and growing capacity investment across Asia Pacific and other emerging research hubs.
The market is driven by the expanding volume of clinical-stage cell and gene therapy programs and rising regulatory emphasis on robust, product-specific potency and biodistribution assays ahead of pivotal and commercial-stage filings.
The Cell Therapy segment dominated the Cell and Gene Therapy Bioanalytical Testing Services Market, accounting for approximately 38.60% share in 2025.
The North America region dominated the Cell and Gene Therapy Bioanalytical Testing Services Market in 2025 with approximately 44.20% revenue share.
